Lyons-Williams Lori 4

What Happened Lori Lyons-Williams, a non-employee director of Contineum Therapeutics, was granted a derivative award — stock options covering 19,000 shares of Class A common stock — on June 26, 2026. The Form 4 records the grant as an acquisition of a derivative security at $0.00 (no cash paid at grant). This is a compensation award under the company’s director program rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; reported same day (filing appears timely).
• Award: Options covering 19,000 shares; reported price $0.00 (grant of derivative, no cash exchange).
• Vesting: Options vest in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, subject to continuous service.
• Plan: Granted under the Issuer’s 2024 Equity Incentive Plan pursuant to the Non‑Employee Director Compensation Program (automatic annual grant for continuing non-employee directors).
• Shares owned after transaction: Not disclosed in this Form 4.

Context This filing documents a standard director compensation grant (options), not an immediate purchase or sale of shares. Such awards are routine for non-employee directors and do not by themselves indicate the director bought or sold stock in the open market. If and when these options are exercised or shares are sold, separate filings would disclose those transactions.